vimarsana.com

Page 25 - ப்ராஸ்டேட் புற்றுநோய் அடித்தளம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Andy D Young

Andy D. Young, age 90, of Coleman, died Monday, December 28, 2020 at Wisteria Place Nursing and Rehabilitation in Abilene. Mr. Young will lie in state starting at 8:00 a.m. to 2:30 p.m. Wednesday, December 30, 2020 at Stevens Funeral Home. A funeral service will be 3:00 p.m. Wednesday, December 30, 2020 at Stevens Funeral Home Chapel, 400 W. Pecan Street, in Coleman with Bob Martin, pulpit minister at Elm Street Church of Christ, officiating. Interment will be in the Burkett Cemetery. Services are entrusted to Stevens Funeral Home in Coleman. The funeral service will be live-streamed and available to view for 90 days. To view the live stream, go to www.livingmemorials.com and click on the obituary page for Andy. The live stream will be at the bottom of his obituary page.

Discovery about how cancer cells evade immune defenses inspires new treatment approach

 E-Mail Cancer cells are known for spreading genetic chaos. As cancer cells divide, DNA segments and even whole chromosomes can be duplicated, mutated, or lost altogether. This is called chromosomal instability, and scientists at Memorial Sloan Kettering have learned that it is associated with cancer s aggressiveness. The more unstable chromosomes are, the more likely that bits of DNA from these chromosomes will end up where they don t belong: outside of a cell s central nucleus and floating in the cytoplasm. Cells interpret these rogue bits of DNA as evidence of viral invaders, which sets off their internal alarm bells and leads to inflammation. Immune cells travel to the site of the tumor and churn out defensive chemicals. A mystery has been why this immune reaction, triggered by the cancer cells, does not spell their downfall.

Senhwa Biosciences Receives US FDA Study May Proceed Letter to Treat BRCA2+ or PALB2+ Solid Tumors With CX-5461

Share: TAIPEI and SAN DIEGO, Dec. 23. 2020 /PRNewswire/ Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next-generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, today announced that it has received a Study May Proceed letter from the US Food and Drug Administration (FDA) to begin a Phase Ib study evaluating CX-5461, a first-in-class G-quadruplex stabilizer, to treat solid tumors with BRCA2 or PALB2 mutations. The FDA s approval of our Phase Ib clinical trial application for testing CX-5461 in patients with BRCA2 or PALB2 mutations is an important milestone and marks a new paradigm in the treatment of cancers with specific pathogenic mutations, stated Dr. John Soong, the Chief Medical Officer of Senhwa Biosciences.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.